NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview OCTOBER 2025

This presentation has been prepared by Citius Pharmaceuticals, Inc . (the “Company”) for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company . This presentation does not purport to be all - inclusive or to contain all of the information you may desire . The information contained in this presentation and the comments and remarks of the representatives of the Company made during any presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together . Information provided in this presentation speaks only as of the date hereof . The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances . This presentation also includes express and implied forward - looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts . Such forward - looking statements may be identified by words such as “believes”, “expects”, “endeavors”, “anticipates”, “intends”, “plans”, “estimates”, “projects”, “should”, “objective” and variations of such words and similar words . The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond the Company’s control that may cause actual results to differ materially from what is presented herein . Investors are strongly encouraged to carefully review the Company’s SEC filings for a listing of the risks that could cause actual results to differ from these forward - looking statements . These forward - looking statements speak only as of the date of this presentation and should not be construed as statements of facts . As a matter of course, we do not make public projections as to our expected sales or profitability due to, among other reasons, the inherent uncertainty of the underlying assumptions and estimates . Similarly, as a matter of course, we do not comment on ongoing or potential partnership discussions, the expected timing of future financial raises or potential long - term strategic plans . NASDAQ: CTXR 2 FORWARD - LOOKING STATEMENTS

INVESTMENT HIGHLIGHTS Biopharmaceutical company with multiple advanced development programs • LYMPHIR (denileukin diftitox - cxdl) • APPROVED for the treatment of cutaneous T - cell lymphoma (CTCL) • Commercialization planned in Q4 2025 • Spun - off into Citius Oncology, Inc. (NASDAQ: CTOR) in August 2024 • Mino - Lok ® • Only treatment designed to salvage infected catheters causing CLABSI • Phase 3 trial completed in 2024 • Positive Topline data – met primary and secondary endpoints • Halo - Lido • Only Rx therapy under development for hemorrhoids • Phase 2b trial completed NASDAQ: CTXR 3

NASDAQ: CTXR ABOUT CITIUS ONCOLOGY, INC. (NASDAQ: CTOR) 4 1. Internal estimates based on IQVIA market research. 2. Intended distribution timing subject to performance, market conditions, and other factors including applicable restrictions on transfer. Biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies • Lead product, LYMPHIR , FDA approved August 2024 • Orphan Indication: treatment of adult patients with relapsed or refractory Stage I - III cutaneous T - cell lymphoma (CTCL) after at least one prior systemic therapy • 12 - year BLA exclusivity • First new systemic CTCL therapy since 2018 • Commercialization planned for Q4 2025 • Estimated $400M+ addressable U.S. market with growth opportunities 1 • Publicly traded on NASDAQ since August 2024 (Ticker: CTOR) • Majority - owned (~79%) subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) • CTXR intends to distribute a portion of its shares of CTOR to CTXR shareholders in the future 2 • Shared management services agreement with CTXR

NASDAQ: CTXR CITIUS IS PREPARING TO LAUNCH LYMPHIR IN Q4 2025 Citius has invested >$90 million in LYMPHIR to date $40M Upfront purchase $43M Development and precommercial efforts $5M Spinout to form Citius Oncology Significant pre - commercial activities have been completed Manufactured inventory for launch Negotiated supply chain and CSO agreements Secured new permanent J - code (HCPCS Level II code – J9161) and inclusion of LYMPHIR in NCCN guidelines Developed targeted machine learning trigger system for salesforce to identify potential patients Initiated marketing strategy to raise brand awareness Hired key sales force management team Additional pre - commercial activities underway Hire and onboard salesforce to initiate sales Ship product to wholesalers Implement digital media plan and ad campaign Launch Patient Services Hub Named Patient Program expansion to ex - US markets Commercial launch readiness nearing completion through disciplined financial strategy 5

NASDAQ: CTXR 6 WHAT IS CUTANEOUS T - CELL LYMPHOMA (CTCL)? Considered to be incurable, CTCL is a Subgroup of Non - Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells CTCL is a general term for T - cell lymphoma that involves the skin, but may also involve the blood, lymph nodes, and internal organs CTCL accounts for approximately 4% of all non - Hodgkin lymphoma (NHL) 1 More prevalent in men than women and usually appears in patients in their 50s and 60s Patients with persistent or recurrent CTCL require systemic therapy 1. Dummer R, et al. Nat Rev Dis Primers. 2021;7(1):61. 2. Rangoonwala, HI and Cascella M. 2022, StatPearls Publishing: Treasure Island, FL. 3. Cleveland Clinic. Cutaneous T - Cell Lymphoma . 2023. Available from: https0://my.clevelandclinic.org/health/diseases/17940 - cutaneous - t - cel l - l ymphoma 4. Hristov AC, et al. Am J Hematol. 2019;94(9):1027 - 1041. 60% 3 - 5% 37% CTCL Prevalence by Subtype 2 Mycosis Fungoides Sezary Syndrome Other CTCL

CTCL PATIENTS HAVE A HIGH DISEASE BURDEN T1 T4 Sézary cell T2 T3 Zackheim. J Am Acad Dermatol. 1999;40:418. Slide credit: clinicaloptions.com NASDAQ: CTXR 7

DIFFERENTIATED MECHANISM OF ACTION (MOA) LYMPHIR targets the IL - 2 receptor, working both as a targeted therapy against malignant T - cells AND as an immunotherapy against Tregs IL - 2 receptor offers a unique treatment opportunity in CTCL Malignant T - cells and Tregs share a common marker: the IL - 2 receptor Targets Malignant Cells Binds to IL - 2 receptors to deliver diphtheria toxin, killing tumor cells directly NASDAQ: CTXR 8 Eliminates Immunosuppressive Tregs Reduces number of Treg cells, subsequently enhancing anti - tumor immunity

COMPETITIVE LANDSCAPE Today’s CTCL treatments are non - curative LYMPHIR excels where current therapies are limited • Requires CD30+ biomarker • Peripheral neuropathy may limit use • Most effective in SS subsegment of CTCL (<5%) • Acts on blood disease rather than skin disease • ORR 21% in MF • Use limited by cumulative bone marrow toxicity • Quality of life issues • No biomarker needed • Broad label • No cumulative toxicity • Skin relief • Rapid response • No cumulative toxicity • No cumulative toxicity • Refined patient profile Limitations NASDAQ: CTXR 9

VERY CONCENTRATED PRESCRIBER BASE 10% of Providers (Physicians) Treat ≥3 Patients 90 17 7 15 12 0 10 20 30 40 50 60 70 Number of Accounts 80 90 100 20 - 40 41 - 60 61 - 80 81 - 120 121 - 475 Number of Patients Accounts by Number of Diagnosed Patients 3928, 90% 427, 10% Providers treating at least 1 patient Providers treating at least 3 patients Source: IQVIA Medical (Dx) & Pharmacy (Rx) Claims Data; IQVIA Citius CTCL HCP Targeting Report – September 2022 Copyright © 2022 IQVIA. All rights reserved. Patients may be double counted if treated by multiple providers. Accounts include institutions with multiple prescribing physicians or centers of care. NASDAQ: CTXR 10 141 Accounts Diagnose ≥20 Patients

PATIENT AND HCPS CLUSTERED NEAR MAJOR CANCER CENTERS • Concentration of providers and accounts allows for a focused field force approach (~ 25 reps) • AI - driven trigger system will direct the field force to optimize opportunities with providers and patients Powered by Bing © GeoNames, Microsoft, TomTom 6 NASDAQ: CTXR 11 COUNT 795 CTCL PATIENTS BY STATE* ( TOTAL PATIENTS = 6 ,841 ) * Source: IQVIA Medical (Dx) & Pharmacy (Rx) Claims Data IQVIA Citius CTCL HCP Targeting Report – September 2022. Cumulative Data 2017 - 2021. Patient State based on patient ZIP 3. US Territories removed from visualization. 60% of CTCL patients are concentrated in 10 states

DISTRIBUTION READINESS AND CHANNEL ACCESS Patient - Centric Distribution Strategy aims to provide timely product availability for eligible CTCL patients across all care settings, reinforcing Citius’ commitment to access • Nationwide U.S. distribution network established • All major distribution agreements operational • Citius Oncology has executed agreements with Cencora, Cardinal Health, and McKesson to support U.S. distribution of LYMPHIR • These partnerships ensure nationwide coverage across academic centers and community clinics • Commercial - ready inventory with a 60 - month shelf life is in place to meet projected demand 12 – 18 months post - launch • Ex - U.S. strategy to leverage country - specific Named Patient Programs • Exclusive distribution agreement with Integris Pharma S.A. (Oct 2025) • Establishes coverage for 12 markets: Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia • Citius Pharma is in active discussions with multiple additional prospective distribution partners across several European Union member states, in South America, and in select Middle Eastern territories NASDAQ: CTXR 12

OPPORTUNITIES FOR GROWTH BEYOND CTCL • University of Pittsburgh: an investigator - initiated trial is underway to evaluate LYMPHIR for potential use as an immuno - oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) • Encouraging preliminary results of interim analysis: • 15 evaluable patients showed 27% ORR; 33% Clinical Benefit Rate; median Progression Free Survival of 57 weeks (for patients that achieved a clinical benefit) • The data supports further evaluation of this combination across a broader range of solid tumor types • Phase 1 Preliminary study data (n=25) anticipated Q4 2025/Q1 2026 • University of Minnesota: LYMPHIR in combination with CAR T therapies (NCT04855253) • Phase 1 study to evaluate the potential benefit of LYMPHIR given prior to CAR T therapy in patients with high risk relapsed/refractory B - cell lymphomas • Preliminary study results anticipated Q1 2026 • Logical label expansion potential in PTCL where there is a high unmet need and no curative therapies Phase III Phase II Phase I Preclinical Investigational Indication Program data published Prelim Interim p C OMBINATION WITH PD - 1 I NHIBITOR (K EYTRUDA ® ) 1 UNIVERSITY OF PITTSBURG MEDICAL CENTER, HILLMAN CANCER CENTER C OMBINATION WITH CAR - T (K YMRIAH ) 1 UNIVERSITY OF MINNESOTA, MASONIC CANCER CENTER P ERIPHERAL T - C ELL L YMPHOMA LYMPHIR - P NASDAQ: CTXR KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation. 13

LYMPHIR IS COMPETITIVELY POSITIONED • Differentiated MOA targeting the IL - 2 receptor reinforces rationale for inclusion among the current core therapeutic options in the U.S. market • CTCL treatments are non - curative , often have a limited duration of response and/or are discontinued early • Patients are put on multiple alternate therapies and cycle to 2nd line treatments within 5 months , on average • Key growth drivers expected to increase overall market size and facilitate market penetration • Evolving treatment paradigm; incremental therapeutic option for pre - treated patients • Historically, market growth has followed introduction of new therapeutics • Competitively priced • No new therapy approved since 2018 Clinical profile and market dynamics supports market entry NASDAQ: CTXR 14

MINO - LOK NASDAQ: CTXR 15 Phase 3 Trial Completed: Positive Topline Data

NASDAQ: CTXR MINO - LOK OVERVIEW Achieved primary and secondary endpoints of Phase 3 Trial x Time to catheter failure exceeded expectations x Majority of patients in the Mino - Lok group achieved overall treatment success x Well tolerated with no drug - related serious adverse events A novel antibiotic lock solution designed to salvage catheters in patients with catheter - related bloodstream infections Mino - Lok addresses the complications, discomfort and cost of catheter removal and replacement No drugs currently approved to salvage catheters in patients with central - line associated bloodstream infections (CLABSI) or catheter - related bloodstream infections (CRBSI) Phase 3 Trial completed: multi - center, randomized, open label, blinded assessor, active control superiority study Estimated global market expected to exceed $2 billion 1 16 1. Market.us. Catheter - Related Bloodstream Infection Market Report. Retrieved from https://market.us/report/catheter - related - bloodstream - infection - market/

CENTRAL VENOUS CATHETERS NASDAQ: CTXR 17 Central Venous Catheters (CVCs), Peripherally Inserted Central Catheter (PICCs), and Hemodialysis Central Venous Catheter PICC Hemodialysis

BIOFILM FORMATION PROTECTS COLONIES • Pathogens attach to the surface of the lumen in a central venous catheter and form colonies. • Colonies grow and exude a fibrous glycocalyx that protects the organisms from antibiotics, even when shown to be sensitive in vitro NASDAQ: CTXR 18

MARKET POTENTIAL: $1B+ IN US AND $2B+ GLOBALLY High incidence of catheter - related infections support need for effective treatment options ~500,000 CRBSI/CLABSI infections annually in the U.S.** 12 - 25% CRBSI/CLABSI associated mortality & morbidity** * Shah H., Bosch W., Hellinger W. C., Thompson K. M. (2013). Intravascular catheter - related bloodstream infection. Neurohospitalist 3, 144 – 151. doi: 10.1177/1941874413476043. ** Antoňáková Němčíková A, Bednárovská E. Catheter - related bloodstream infections: do we know all of it? Klin Onkol. 2017;30(6):405 – 411. doi: 10.14735/amko2017405. NASDAQ: CTXR 19 4 million Long - term CVCs (>1 month) in the U.S.* 7 million Central Venus Catheters (CVCs) used annually in the U.S.*

POTENTIAL TO CHANGE STANDARD OF CARE Mino - Lok addresses the complications, discomfort and cost of CVC removal and replacement salvage existing catheters Limited duration IV therapy designed to eradicate bacterial colonization with a short 2 - hour dwell time Limits disruption of infusion therapy allowing continued use of the catheter for intended treatments Ease of Administration: Locking a catheter is a well - known standard operating procedure Non - invasive and adjunct to systemic therapy Lowers risks to patient Lower cost alternative: significantly less than removal and replacement NASDAQ: CTXR 20

MINO - LOK PHASE 3 TRIAL TOPLINE RESULTS NASDAQ: CTXR 21 Mino - Lok significantly outperforms hospital - specific anti - infective lock solutions • Kaplan Meier Analysis demonstrated clear separation between Mino - Lok and control arms, illustrating Mino - Lok’s superiority in extending time to catheter failure Control arm: 33 days Mino - Lok arm: exceeded the trial period (6 weeks) (p - value = 0.0006) Primary Endpoint: Median Time to Failure A greater percentage of patients in the Mino - Lok arm achieved overall treatment success compared to the control arm (p - value = 0.0025) Key Secondary Endpoint: Overall Treatment Success Mino - Lok was well - tolerated with no drug - related serious adverse events Comparable adverse events between Mino - Lok (45.1%) and control (46.1%) arms, as expected in very ill patients Mino - Lok is instilled into the catheter and never enters the patient Safety Profile

HALO - LIDO NASDAQ: CTXR 22 Halobetasol/Lidocaine

NASDAQ: CTXR • 10+ Million patients report symptoms of hemorrhoidal disease; 1/3 seek physician treatment 1 • A cream formulation containing halobetasol propionate (highly potent steroid) and Lidocaine HCl • Phase 2b enrollment completed • 5 cohorts of 60 subjects each • Primary endpoint: reduction in hemorrhoidal symptoms • Subject self - reported using proprietary mobile app (PRO) • Positive Phase 2b results • Meaningful reduction in symptom severity when compared to individual components alone • Dose for Phase 3 trial selected • Trial validates Patient Reported Outcome (PRO) instrument developed to support a pivotal Phase 3 study • Ongoing FDA engagement regarding next steps over the coming months • Citius anticipates monetizing the value of this asset with a strategic or financial partner HALO - LIDO OVERVIEW Potentially the first FDA - approved prescription product to treat hemorrhoids 1. Source: https: //www.mayoclinic.org/medical - professionals/digestive - diseases/news/hemorrhoidal - disease - diagnosis - and - management/mac - 20430067 23

SUMMARY NASDAQ: CTXR 24

WHY INVEST? WHY NOW? NASDAQ: CTXR 25 Diversified late - stage biopharmaceutical company with commercialization anticipated in 2025 • LYMPHIR poised to launch in Q4 2025 • $400+M est. addressable market with multiple opportunities for growth • First new systemic CTCL therapy since 2018 • 12 - year BLA exclusivity • Pipeline of additional late - stage assets • Management and shareholder alignment • $26.5 M invested by founders • Successful pharma/biotech track record • Attractive investor entry points

NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Investor Inquiries ir@citiuspharma.com